Helicobacter pylori infection and the risks of Barrett's oesophagus: A population‐based case–control study

Infection with Helicobacter pylori is associated with significantly reduced risks of oesophageal adenocarcinoma; however, few studies have examined the association between H. pylori and Barrett's oesophagus (BO), the precursor lesion. We explored the relationship between H. pylori infection and BO and sought to identify potential modifiers. We compared the prevalence of positive H. pylori serology among 217 adults with simple BO (without dysplasia), 95 with dysplastic BO and 398 population controls sourced from the metropolitan Brisbane area. We determined H. pylori serostatus using enzyme‐linked immunosorbent assay. To estimate relative risks, we calculated odds ratios (OR) and 95% confidence intervals (CI) using multivariable logistic regression in the entire sample and stratified by factors known to cause BO. The prevalence of H. pylori seropositivity was 12%, 3%, and 18%, respectively, among patients with simple BO, dysplastic BO and population controls. BO patients were significantly less likely to have antibodies for H. pylori (Simple BO: OR = 0.51, 95% CI: 0.30–0.86; Dysplastic BO: OR = 0.10, 95% CI: 0.03–0.33) than population controls. For simple BO, the association was diminished after adjustment for frequency of gastro‐oesophageal reflux (GOR) symptoms. Adjustment for frequency of GOR symptoms did not substantially alter the observed effect for dysplastic BO. Although there was some variation in the magnitude of risk estimates across strata of age, sex, GOR symptoms and use of proton pump inhibitors or H2‐receptor antagonists, the differences were uniformly nonsignificant. Helicobacter pylori infection is inversely associated with BO, and our findings suggest that decreased acid load is not the only mechanism underlying the H. pylori protective effect.

[1]  Z. Zhao,et al.  Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. , 2010, Gastroenterology.

[2]  H. Welch,et al.  Esophageal Adenocarcinoma Incidence: Are We Reaching the Peak? , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[3]  Gail M. Williams,et al.  Do low control response rates always affect the findings? Assessments of smoking and obesity in two Australian case‐control studies of cancer , 2009, Australian and New Zealand journal of public health.

[4]  D. Whiteman,et al.  Current and past smoking significantly increase risk for Barrett's esophagus. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  R. Hunt,et al.  Helicobacter pylori Infection and Barrett's Esophagus: A Systematic Review and Meta-Analysis , 2009, The American Journal of Gastroenterology.

[6]  K. Hahm,et al.  The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease , 2008, Journal of gastroenterology and hepatology.

[7]  M. Blaser Disappearing Microbiota: Helicobacter pylori Protection against Esophageal Adenocarcinoma , 2008, Cancer Prevention Research.

[8]  F. Islami,et al.  Helicobacter pylori and Esophageal Cancer Risk: A Meta-analysis , 2008, Cancer Prevention Research.

[9]  W. Chow,et al.  Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. , 2008, Journal of the National Cancer Institute.

[10]  T. Rokkas,et al.  Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  H. Comber,et al.  Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case–control study , 2007, Gut.

[12]  Jacques Ferlay,et al.  Trends in oesophageal cancer incidence and mortality in Europe , 2007, International journal of cancer.

[13]  D. Gotley,et al.  Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus , 2007, Gut.

[14]  D. Forman,et al.  Risk of Mortality and Cancer Incidence in Barrett's Esophagus , 2007, Cancer Epidemiology Biomarkers & Prevention.

[15]  G. Block,et al.  Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study , 2007, Gut.

[16]  D. Corley,et al.  Serum Ghrelin Levels and Risk of Subsequent Adenocarcinoma of the Esophagus , 2007, The American Journal of Gastroenterology.

[17]  K. McColl Helicobacter pylori and oesophageal cancer—not always protective , 2007, Gut.

[18]  D. Corley,et al.  Body Mass Index and Adenocarcinomas of the Esophagus or Gastric Cardia: A Systematic Review and Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[19]  H. El‐Serag,et al.  Meta-Analysis: Obesity and the Risk for Gastroesophageal Reflux Disease and Its Complications , 2005, Annals of Internal Medicine.

[20]  C. de Martel,et al.  Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. , 2005, The Journal of infectious diseases.

[21]  Joseph K McLaughlin,et al.  Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. , 2004, Journal of the National Cancer Institute.

[22]  M. Blaser,et al.  Helicobacter pylori persistence: biology and disease. , 2004, The Journal of clinical investigation.

[23]  H. Randeva,et al.  Plasma ghrelin following cure of Helicobacter pylori , 2003, Gut.

[24]  Y. Sugisaki,et al.  Effect of Helicobacter pylori Infection on Ghrelin Expression in Human Gastric Mucosa , 2004, The American Journal of Gastroenterology.

[25]  G. Triadafilopoulos,et al.  Prevalence of Barrett's esophagus in asymptomatic individuals. , 2002, Gastroenterology.

[26]  T. Azuma,et al.  Eradication of Helicobacter pylori infection induces an increase in body mass index , 2002, Alimentary pharmacology & therapeutics.

[27]  M. Go Natural history and epidemiology of Helicobacter pylori infection , 2002, Alimentary pharmacology & therapeutics.

[28]  G. Berglund,et al.  Helicobacter pylori Infection is Associated with a Decreased Risk of Developing Oesophageal Neoplasms , 2001, Helicobacter.

[29]  E. El-Omar,et al.  Helicobacter pylori gastritis and gastric physiology. , 2000, Gastroenterology clinics of North America.

[30]  H. Rautelin,et al.  Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy , 2000, Gut.

[31]  M. Carrington,et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.

[32]  A. Andriulli,et al.  Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying , 1998, American Journal of Gastroenterology.

[33]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[34]  R. Hunt,et al.  Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. , 1998, Gastroenterology.

[35]  V. Thursfield,et al.  Rising incidence of oesophageal adenocarcinoma in men in Australia , 1998, Journal of gastroenterology and hepatology.

[36]  A B West,et al.  An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. , 1998, Cancer research.

[37]  E. El-Omar,et al.  Helicobacter pylori infection and chronic gastric acid hyposecretion. , 1997, Gastroenterology.

[38]  E. El-Omar,et al.  Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. , 1995, Gastroenterology.

[39]  C. Pusey,et al.  Long-term sequelae of Helicobacter pylori gastritis , 1995, The Lancet.

[40]  G. Maconi,et al.  Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of helicobacter pylori in duodenal ulcer patients. A controlled study. , 1995, Gut.

[41]  A. Cameron,et al.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium. , 1992, Gastroenterology.

[42]  D J Ballard,et al.  Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. , 1990, Gastroenterology.

[43]  W S Payne,et al.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.

[44]  K. Behrns Association of Helicobacter pylori Infection With Reduced Risk for Esophageal Cancer Is Independent of Environmental and Genetic Modifiers , 2012 .

[45]  D. Forman,et al.  A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. , 2008, The American journal of gastroenterology.

[46]  D. Watson,et al.  Prevalence of Symptoms and Use of Medication for Gastroesophageal Reflux in an Australian Community , 2008, World Journal of Surgery.

[47]  R. Holmes,et al.  Epidemiology and pathogenesis of esophageal cancer. , 2007, Seminars in radiation oncology.

[48]  B. Sheppard,et al.  Helicobacter pylori induces apoptosis in Barrett’s-derived esophageal adenocarcinoma cells , 2003, Journal of Gastrointestinal Surgery.

[49]  R. Sampliner,et al.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus , 2002, American Journal of Gastroenterology.

[50]  P. Dítě,et al.  [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.